GlycoMimetics to Present at Two Upcoming Investor Conferences
November 13 2019 - 9:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq:
GLYC) today announced that company executives will provide a
corporate update at two upcoming investor relations conferences in
November. Details are as follows:
STIFEL HEALTHCARE CONFERENCE (NEW
YORK) Date: Tuesday, November 19, 2019 Time: 4:10 p.m. ET
Presenter: GlycoMimetics CFO Brian Hahn
JEFFERIES 2019 LONDON Healthcare
Conference Date: Thursday, November 21, 2019 Time: 7:20 a.m.
GMT Presenter: GlycoMimetics CEO Rachel King
To access the live webcast and subsequent archived recordings
for this presentation, please visit the GlycoMimetics website at
www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on the discovery and development of novel glycomimetic drugs to
address unmet medical needs resulting from diseases in which
carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned
drug candidate, uproleselan, an E-selectin antagonist, was
evaluated in a Phase 1/2 clinical trial as a potential treatment
for AML and is being evaluated across a range of patient
populations including a Company-sponsored Phase 3 trial in
relapsed/refractory AML. GlycoMimetics has also completed a Phase 1
clinical trial with another wholly-owned drug candidate, GMI-1359,
a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191113005042/en/
Investor Contact: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310
Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Sep 2023 to Sep 2024